eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Flynn Pharma Ltd

Alton House, 4 Herbert Street, Dublin 2, Republic of Ireland,
Telephone: +44 (0)1438 727822
Fax: +44 (0)1438 727805
WWW: http://www.flynnpharma.com
Medical Information Direct Line: +44 (0)1438 727822
Medical Information e-mail: medinfo@flynnpharma.com
Customer Care direct line: +44 (0)1773 510 123
Medical Information Fax: +44 (0)1438 727805

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 21/12/2011
SPC Medikinet Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 21/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   12-Jul-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



In Section 4.2 The following section has changed to read:

The last doses should, in general, not be given within 4 hours before bedtime in order to prevent disturbances in falling asleep.However, if the effect of the medicinal product wears off too early in the evening, disturbed behaviour may recur. A small evening dose may help to solve this problem.The pros and cons of a small evening dose versus disturbances in falling asleep should be considered.

In Section 4.4 the following wording has been added to the end of the "aggressive or hostile behaviour" section:

...., bearing in mind that upwards or downwards titration may be appropriate . Treatment interruption can be considered.

In Section 10 the revised date is 12th July 2011

Updated on 24/06/2010 and displayed until 21/12/2011
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   03-Feb-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Changes to the SmPC
Updated on 30/04/2007 and displayed until 24/06/2010
Reasons for adding or updating:
  • New SPC for new product
  • SPC Submitted in error

Active Ingredients/Generics

 
   methylphenidate hydrochloride